Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 6/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4016289 | 0.90 | MEN1 (0.55) | MEN1KMT2AMALT1PAK1DRD4 | |
| SCHEMBL4016380 | 0.88 | USP30 (0.52) | PAK1DRD4CCNE1CDK2DRD2 | |
| SCHEMBL4019291 | 0.81 | PAK1 (0.63) | MEN1KMT2AMALT1PAK1DRD4 | |
| SCHEMBL4020162 | 0.79 | DRD4 (0.55) | MEN1KMT2AMALT1PAK1DRD4 | |
| SCHEMBL4020892 | 0.77 | PDGFRB (0.49) | MEN1KMT2ADRD4CCNE1CDK2 | |
| SCHEMBL4016031 | 0.76 | PAK1 (0.46) | MEN1KMT2AMALT1PAK1DRD4 | |
| SCHEMBL4023811 | 0.76 | PAK1 (0.60) | MEN1KMT2AMALT1PAK1DRD4 | |
| SCHEMBL4024515 | 0.75 | PAK1 (0.56) | MEN1KMT2AMALT1PAK1DRD4 | |
| SCHEMBL4016402 | 0.75 | MEN1 (0.56) | MEN1KMT2APAK1DRD4DRD2 | |
| SCHEMBL4024322 | 0.74 | MAPT (0.58) | KMT2AMALT1PAK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066654-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | Bayer Schering Pharma AG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008028691-A1 | N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |